Terminated PHASE1 INTERVENTIONAL 2-arm NCT00887445

First in Man Study With SLV341

A Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV341 in Young Healthy Male Subjects

Sponsor: Quintiles, Inc.

Conditions Diabetes

Interventions SLV341 placebo

Updated 6 times since 2017 Last updated: Apr 27, 2010 Started: Jul 31, 2008 Primary completion: May 31, 2009 Completion: May 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was terminated on June 25th, 2009 due to strategic decision

Other terminated trials from Quintiles, Inc.

More terminations from Quintiles, Inc.

Other Diabetes trials with similar outcome

NCT01627899 · Phase NA · Jul 2013

Browse all Diabetes trials

This PHASE1 trial investigates Diabetes and is currently terminated or withdrawn. Quintiles, Inc. leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Jul 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Quintiles, Inc.
Solvay Pharmaceuticals

Data source: Solvay Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom